The University of Chicago Header Logo

Connection

Ernst Robert Lengyel to Ovarian Neoplasms

This is a "connection" page, showing publications Ernst Robert Lengyel has written about Ovarian Neoplasms.
Connection Strength

17.839
  1. 5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer. Gynecol Oncol. 2024 Mar; 182:82-90.
    View in: PubMed
    Score: 0.601
  2. Adipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis. Nat Metab. 2023 09; 5(9):1563-1577.
    View in: PubMed
    Score: 0.584
  3. Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort. JAMA Netw Open. 2023 Jul 03; 6(7):e2323289.
    View in: PubMed
    Score: 0.578
  4. Decoding evolutionary trajectories of ovarian cancer metastasis. Cancer Cell. 2023 06 12; 41(6):1008-1010.
    View in: PubMed
    Score: 0.576
  5. Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront. Cancer Res. 2023 05 02; 83(9):1383-1385.
    View in: PubMed
    Score: 0.571
  6. The adipocyte microenvironment and cancer. Cancer Metastasis Rev. 2022 09; 41(3):575-587.
    View in: PubMed
    Score: 0.543
  7. Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer. Cancer Res. 2022 01 01; 82(1):169-176.
    View in: PubMed
    Score: 0.515
  8. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstet Gynecol. 2021 01 01; 137(1):108-121.
    View in: PubMed
    Score: 0.486
  9. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer? JAMA Netw Open. 2020 08 03; 3(8):e2014184.
    View in: PubMed
    Score: 0.472
  10. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. Cancer Res. 2020 04 15; 80(8):1748-1761.
    View in: PubMed
    Score: 0.457
  11. Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis. Mol Cancer Ther. 2020 01; 19(1):52-62.
    View in: PubMed
    Score: 0.445
  12. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecol Oncol. 2019 02; 152(2):228-234.
    View in: PubMed
    Score: 0.420
  13. The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. Trends Cancer. 2018 08; 4(8):517-519.
    View in: PubMed
    Score: 0.408
  14. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018 04; 37(17):2285-2301.
    View in: PubMed
    Score: 0.397
  15. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018 01; 148(1):204-212.
    View in: PubMed
    Score: 0.391
  16. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351.
    View in: PubMed
    Score: 0.362
  17. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene. 2015 Nov 26; 34(48):5923-32.
    View in: PubMed
    Score: 0.326
  18. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun. 2015 Feb 05; 6:6220.
    View in: PubMed
    Score: 0.323
  19. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015 Apr; 212(4):479.e1-479.e10.
    View in: PubMed
    Score: 0.316
  20. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014 Oct; 124(10):4614-28.
    View in: PubMed
    Score: 0.314
  21. Three-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev. 2014 Dec 15; 79-80:184-92.
    View in: PubMed
    Score: 0.310
  22. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther. 2013 Dec; 12(12):2628-39.
    View in: PubMed
    Score: 0.294
  23. Epithelial ovarian cancer experimental models. Oncogene. 2014 Jul 10; 33(28):3619-33.
    View in: PubMed
    Score: 0.291
  24. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012 Dec; 2(12):1100-8.
    View in: PubMed
    Score: 0.277
  25. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7.
    View in: PubMed
    Score: 0.260
  26. The effects of 17ß-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol. 2012 Jan; 124(1):134-41.
    View in: PubMed
    Score: 0.256
  27. The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov. 2011 Jul; 1(2):100-2.
    View in: PubMed
    Score: 0.251
  28. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011 Jun 15; 17(12):4042-51.
    View in: PubMed
    Score: 0.249
  29. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011 Feb 01; 17(3):459-71.
    View in: PubMed
    Score: 0.242
  30. Ligand-independent activation of c-Met by fibronectin and a(5)ß(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011 Mar 31; 30(13):1566-76.
    View in: PubMed
    Score: 0.241
  31. Ovarian cancer development and metastasis. Am J Pathol. 2010 Sep; 177(3):1053-64.
    View in: PubMed
    Score: 0.236
  32. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010 Jan; 12(1):1-10.
    View in: PubMed
    Score: 0.227
  33. {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 2009 Nov; 175(5):2184-96.
    View in: PubMed
    Score: 0.223
  34. Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila). 2009 Sep; 2(9):792-9.
    View in: PubMed
    Score: 0.222
  35. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle. 2009 Mar 01; 8(5):683-8.
    View in: PubMed
    Score: 0.214
  36. Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res. 2009; 149:335-51.
    View in: PubMed
    Score: 0.212
  37. Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol. 2008 Nov; 111(2):173-8.
    View in: PubMed
    Score: 0.208
  38. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008 Apr; 118(4):1367-79.
    View in: PubMed
    Score: 0.201
  39. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008 Apr 01; 68(7):2329-39.
    View in: PubMed
    Score: 0.201
  40. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9.
    View in: PubMed
    Score: 0.186
  41. Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis. JCI Insight. 2023 03 22; 8(6).
    View in: PubMed
    Score: 0.142
  42. Ovarian Masses: The Value of Acoustic Shadowing on Ultrasound Examination. J Ultrasound Med. 2023 Apr; 42(4):935-945.
    View in: PubMed
    Score: 0.137
  43. Resilience in the Face of Pandemic: The Impact of COVID-19 on the Psychologic Morbidity and Health-Related Quality of Life Among Women With Ovarian Cancer. JCO Oncol Pract. 2022 06; 18(6):e948-e957.
    View in: PubMed
    Score: 0.132
  44. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. Gynecol Oncol. 2021 10; 163(1):130-133.
    View in: PubMed
    Score: 0.127
  45. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001 Aug; 7(8):2396-404.
    View in: PubMed
    Score: 0.126
  46. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001 Aug; 82(2):291-8.
    View in: PubMed
    Score: 0.126
  47. The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. Cancer Res. 2021 08 01; 81(15):3985-4000.
    View in: PubMed
    Score: 0.125
  48. Mesothelial Cell HIF1a Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Rep. 2019 12 17; 29(12):4086-4098.e6.
    View in: PubMed
    Score: 0.113
  49. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 06 15; 125(12):1963-1972.
    View in: PubMed
    Score: 0.107
  50. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 04; 17(4):870-881.
    View in: PubMed
    Score: 0.106
  51. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019 01 07; 216(1):176-194.
    View in: PubMed
    Score: 0.105
  52. A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. Biomaterials. 2019 01; 190-191:63-75.
    View in: PubMed
    Score: 0.104
  53. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 2019 01 08; 29(1):141-155.e9.
    View in: PubMed
    Score: 0.103
  54. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018 11 01; 24(21):5357-5367.
    View in: PubMed
    Score: 0.101
  55. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 07; 146(1):153-160.
    View in: PubMed
    Score: 0.094
  56. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.
    View in: PubMed
    Score: 0.093
  57. Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res. 2017 04 01; 77(7):1684-1696.
    View in: PubMed
    Score: 0.093
  58. A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discov. 2017 06; 22(5):494-506.
    View in: PubMed
    Score: 0.093
  59. Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metab. 2016 11 08; 24(5):728-739.
    View in: PubMed
    Score: 0.091
  60. Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Mol Cancer Res. 2017 01; 15(1):78-92.
    View in: PubMed
    Score: 0.091
  61. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun. 2016 08 26; 7:12645.
    View in: PubMed
    Score: 0.090
  62. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther. 2016 10; 15(10):2282-2293.
    View in: PubMed
    Score: 0.089
  63. Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. J Vis Exp. 2015 12 31; (106):e53541.
    View in: PubMed
    Score: 0.086
  64. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov; 15(11):668-79.
    View in: PubMed
    Score: 0.085
  65. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015 Sep 15; 6(27):23548-60.
    View in: PubMed
    Score: 0.084
  66. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62.
    View in: PubMed
    Score: 0.083
  67. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 May 28; 521(7553):489-94.
    View in: PubMed
    Score: 0.082
  68. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget. 2015 May 10; 6(13):11342-56.
    View in: PubMed
    Score: 0.082
  69. WNT7A/ß-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 2015 Jun; 34(26):3452-62.
    View in: PubMed
    Score: 0.078
  70. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One. 2014; 9(8):e104521.
    View in: PubMed
    Score: 0.078
  71. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014 Jan; 184(1):271-81.
    View in: PubMed
    Score: 0.075
  72. Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting. Gynecol Oncol. 2013 Jul; 130(1):6-8.
    View in: PubMed
    Score: 0.072
  73. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin a5 expression. Am J Pathol. 2013 May; 182(5):1876-89.
    View in: PubMed
    Score: 0.071
  74. Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. Gynecol Oncol. 2013 Apr; 129(1):120-3.
    View in: PubMed
    Score: 0.069
  75. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest. 2012 Oct; 122(10):3603-17.
    View in: PubMed
    Score: 0.068
  76. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011 Oct 30; 17(11):1498-503.
    View in: PubMed
    Score: 0.064
  77. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23; 11(10):719-25.
    View in: PubMed
    Score: 0.064
  78. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012 Apr 15; 130(8):1787-97.
    View in: PubMed
    Score: 0.063
  79. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil Steril. 2010 Sep; 94(4):1212-1217.
    View in: PubMed
    Score: 0.055
  80. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007 Oct 01; 121(7):1463-72.
    View in: PubMed
    Score: 0.048
  81. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007 Nov 01; 6(21):2585-90.
    View in: PubMed
    Score: 0.048
  82. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A. 2007 Jul 03; 104(27):11400-5.
    View in: PubMed
    Score: 0.048
  83. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem. 2001 Jul 13; 276(28):26340-8.
    View in: PubMed
    Score: 0.031
  84. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728.
    View in: PubMed
    Score: 0.027
  85. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16.
    View in: PubMed
    Score: 0.026
  86. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem. 1995 Sep 29; 270(39):23007-12.
    View in: PubMed
    Score: 0.021
  87. A phase II, single-arm study of the anti-a5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011 May 01; 121(2):273-9.
    View in: PubMed
    Score: 0.015
  88. CD95 promotes tumour growth. Nature. 2010 May 27; 465(7297):492-6.
    View in: PubMed
    Score: 0.015
  89. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 2009 Jan; 17(1):57-67.
    View in: PubMed
    Score: 0.013
  90. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008 Apr 01; 22(7):894-907.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.